Navigation Links
Memantine and Alzheimer's disease
Date:1/10/2008

Amsterdam, January 9, 2008 In a study published this month in the Journal of Alzheimer's Disease, researchers from the University of Aberdeen report that the drug memantine, used for the treatment of Alzheimer's disease and praised as "the first and only representative of a new class of Alzheimer drugs" works in fact similar to other existing compounds, and is beneficial only in a narrow concentration range. They further indicate that the complex pharmacological profile of memantine requires careful consideration concerning suitable doses and suitable patient groups, so that the best use can be achieved for patients suffering from Alzheimer's disease.

Dementia is an ever-increasing problem in todays aging societies, with millions of patients and their carers affected worldwide. About one in five people over the age of 80 suffers from Alzheimers disease, the most common type of dementia. There is no cure and little hope is available for treatment, thus leaving the prospect of years or even decades of progressive mental deterioration.

In Alzheimers disease, two systems necessary for the communication of brain cells fail: The stimulatory brain messenger acetylcholine is down-regulated, while over-activation of the messenger glutamate leads to the death of neurones.

The first-generation of compounds aimed to boost the brains acetylcholine levels led to the development of drugs such as Aricept (donepezil) and Excelon (rivastigmine). Attempts to develop drugs that block the action of glutamate by a considerable number of pharmaceutical companies and researchers were not successful for a long time, since these receptors are also required for normal brain function, learning and memory in particular. It was therefore considered a major breakthrough when a drug called memantine was discovered to have beneficial effects in Alzheimers disease, which did not affect the normal function of glutamate signalling, but only the excessive action
'/>"/>

Contact: Astrid Engelen
a.engelen@iospress.nl
31-206-883-355
IOS Press
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Neurobiological Technologies Reports $2.1 Million Quarterly Payment for Sales of Memantine
2. Smoking may strongly increase long-term risk of eye disease
3. Pot bellies linked to early signs of cardiovascular disease
4. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
5. Radiologists encouraged to look beyond cancer for clinically unseen diseases
6. Use of certain lipid measures not more effective in predicting coronary heart disease
7. Role seen for cannabis in helping to alleviate allergic skin disease
8. New prion protein discovered by Canadian scientists may offer insight into mad cow disease
9. Effectiveness of mouse breeds that mimic Alzheimers disease symptoms questioned
10. New research shows how chronic stress worsens neurodegenerative disease course
11. A new molecular zip code, and a new drug target for Huntingtons disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... (PRWEB) August 29, 2014 VHA Central ... for excellence in clinical care, honoring nine facilities for ... patient experience. , “At Novant Health, providing quality, affordable ... priority” said Tom Zweng, MD, executive vice president and ... to provide a remarkable experience for each and every ...
(Date:8/29/2014)... For the fifth year in a ... be observing September 26th as Mesothelioma Awareness Day, by ... York. , Members of the community who wish ... Foundation will be providing t-shirts and signs to participating ... members have received attention from Al Roker ...
(Date:8/29/2014)... 2014 Parker Waichman LLP, a national ... the rights of victims who have been injured by ... announced new regulations for all hydrocodone combination products. According ... report dated August 21, 2014, the DEA will be ... federal law. , The long-awaited announcement comes after ...
(Date:8/29/2014)... Empty Nest Syndrome on Dr. Carol ... , Mothers and fathers, who dedicated the last ... laughing and sweating through parenting, launch their college ... Relief and parenting pride intermix with loss, depression ... Carol Francis as a Clinical Psychologist has helped ...
(Date:8/29/2014)... 2014 Bedros Keuilian recently stepped outside his ... expert on the new Spike TV reality show, Gym ... searched Google for an expert in boot camp marketing and ... Now Keuilian has just released a webinar explaining how fitness ... status as experts and increase their client base. , In ...
Breaking Medicine News(10 mins):Health News:Novant Health Recognized for Excellence in Clinical Care 2Health News:Novant Health Recognized for Excellence in Clinical Care 3Health News:Organization to Raise Awareness of Mesothelioma on the Today Show 2Health News:The Drug Enforcement Agency (DEA) Just Announced Plans to Regulate All Hydrocodone Combination Drugs as Schedule II Drugs, Parker Waichman LLP Comments 2Health News:The Drug Enforcement Agency (DEA) Just Announced Plans to Regulate All Hydrocodone Combination Drugs as Schedule II Drugs, Parker Waichman LLP Comments 3Health News:Psychologist Dr. Carol Francis Addressing Empty-Nest Syndrome on Talk Radio Today 2Health News:Psychologist Dr. Carol Francis Addressing Empty-Nest Syndrome on Talk Radio Today 3Health News:Boot Camp Marketing Expert Bedros Keuilian Releases New Webinar on Using YouTube to Build Credibility and Clientele 2Health News:Boot Camp Marketing Expert Bedros Keuilian Releases New Webinar on Using YouTube to Build Credibility and Clientele 3
... 1 Arete Therapeutics Inc. today,announced the initiation ... lead compound,AR9281, for the treatment of hypertension. AR9281 ... (s-EH), a novel target,for the treatment of hypertension. ... volunteers and will evaluate the safety, tolerability,pharmacokinetics and ...
... 1 Amira Pharmaceuticals, Inc. announced,completion of the ... discovered oral drug candidate for the treatment of ... announced the start,of a Phase 1 trial for ... the,same inflammatory response. AM103 and AM803 are ...
... NAPLES, Fla., Nov. 1 MediaBrains Inc., a ... http://www.agingcare.com . The,website will focus on the needs ... for connecting caregivers with expert information,resources, products and ... Month. The caregiver market represents one of ...
... BASINGSTOKE, England and PHILADELPHIA, November 1, Shire plc (LSE: SHP, ... for the third,quarter 2007. Q3 2007 Financial Highlights ... Total revenues up 35% to $608.7 million; - Net ... and - 2007 revenue growth now expected to be ...
... Innovative Approach to Preventing Kidney Damage during ... ... (Amex: PLC ), a,company focused on innovative cardiac and vascular ... Renal Week, the American Society of Nephrology,s 40th,Annual Meeting and Scientific ...
... of the cells might lead to treatments, researchers say , THURSDAY, ... found stem cells within the intervertebral discs of the human spine. ... stem cells to help repair degenerating discs in order to treat ... the Nov. 1 issue of the journal Spine . , ...
Cached Medicine News:Health News:Arete Therapeutics Initiates Phase 1 Clinical Trial For AR9281 as a First-in-Class Antihypertensive Agent 2Health News:Arete Therapeutics Initiates Phase 1 Clinical Trial For AR9281 as a First-in-Class Antihypertensive Agent 3Health News:Amira Pharmaceuticals Announces Favorable Phase 1 Clinical Trial Results for Lead Product Candidate AM103 and Initiates Clinical Studies for the 2nd Entry Molecule for the Treatment of Respiratory and Cardiovascular Disease 2Health News:Amira Pharmaceuticals Announces Favorable Phase 1 Clinical Trial Results for Lead Product Candidate AM103 and Initiates Clinical Studies for the 2nd Entry Molecule for the Treatment of Respiratory and Cardiovascular Disease 3Health News:Agingcare.com Launches to Meet Information and Networking Demands for Booming 34 Million Caregiver Market 2Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 2Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 3Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 4Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 5Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 6Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 7Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 8Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 9Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 10Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 11Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 12Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 13Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 14Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 15Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 16Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 17Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 18Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 19Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 20Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 21Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 22Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 23Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 24Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 25Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 26Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 27Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 28Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 29Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 30Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 31
(Date:8/29/2014)... UNION CITY, Calif. , Aug. 29, 2014 /PRNewswire/ ... products company manufacturing point-of-care blood instrumentation and consumables to ... Clint Severson , Chairman and Chief Executive Officer, ... Annual Best Ideas Conference 2014 on Tuesday, September 9, ... held at the Omni Berkshire Place Hotel in ...
(Date:8/29/2014)... , Aug. 29, 2014  Pacific Medical Data ... new website design . The main website, along ... showcases the company,s new services and content relevant to ... a new streamlined design, viewers can now better understand ... health care practices and create a more visible platform ...
(Date:8/29/2014)... MENLO PARK, Calif. , Aug. 29, 2014 ... DMPI) ("DelMar" "the Company") today announced the filing of ... recently changed its fiscal year end to June 30th ... common stock on a national securities exchange in the ... filed with the United States Securities Exchange Commission can ...
Breaking Medicine Technology:Abaxis, Inc. to Present at CL King's 12th Annual Best Ideas Conference 2014 2PMDS Announces New Website 2DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 2DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 4DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 5
... Inc. (Nasdaq: OPTR ) today announced it expects ... after the NASDAQ Global Market closes on Thursday, March 10, ... that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific ... fourth quarter and full year 2010, as well as provide ...
... CRANBURY, N.J., March 3, 2011 Palatin Technologies, Inc. (NYSE ... Food and Drug Administration (FDA) has cleared Palatin,s request to ... New Drug (IND) application using a subcutaneously administered formulation of ... acute exacerbations of asthma. "We are excited ...
Cached Medicine Technology:Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2010 Financial Results 2FDA Clears Palatin Technologies' IND Filing to Commence Clinical Studies for Asthma 2
... speed and accuracy allow clinical staff ... timely manner - something everyone in ... In fact, the Rapidlab 1200 delivers ... one minute. Its maintenance-free, cartridge-based system ...
... Fibertom is a 60 watt diode continuous wave ... of Diode Power Bar technology and 940 nm ... laser treatment for varicose veins and a variety ... includes unique safety features including the LPS, Light ...
... 28 Hue test studies the characteristic ... Farnsworth D15, however this 28 hue ... of sensitivity. Case comes with a ... readable. Kit includes laminated scoring template ...
... disc test for detecting and grading ... minutes for quantitative estimation of saturation ... sensitive to and specific for differences ... Combined with Ishiharas pseudo-isochromatic plates, discriminates ...
Medicine Products: